Catheter Precision Enters Securities Purchase Agreement

An update from Catheter Precision ( (VTAK) ) is now available.

On May 12, 2025, Catheter Precision, Inc. entered into a Securities Purchase Agreement with three investors, selling 1.5 million shares of its Series B Convertible Preferred Stock and issuing an additional 1.5 million shares as consideration for existing senior secured Convertible Promissory Notes of QHSLab, Inc. The company has reserved up to 8,574,000 shares of common stock for conversion and issued Series L warrants for purchasing up to 4,285,716 shares of common stock. The conversion and exercise of these securities are subject to stockholder approval, which the company plans to seek at its Annual Meeting on July 25, 2025. The Series B Convertible Preferred Stock has a fixed conversion price of $0.35 per share, while the Series L warrants have a 5 ½ year term and are exercisable at $0.50 per share. The securities offering was conducted under an exemption from registration requirements, and the company intends to register the shares for resale by May 27, 2025.

Spark’s Take on VTAK Stock

According to Spark, TipRanks’ AI Analyst, VTAK is a Underperform.

VTAK’s overall stock score reflects significant challenges in financial performance, particularly in achieving profitability and generating positive cash flows. Technical analysis indicates a bearish trend, with the stock trading below key moving averages. Valuation remains unattractive due to ongoing losses and a negative P/E ratio. While the corporate event of an executive stock option plan is positive, it does not materially improve the current financial and technical outlook.

To see Spark’s full report on VTAK stock, click here.

More about Catheter Precision

Average Trading Volume: 204,548

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.72M

See more insights into VTAK stock on TipRanks’ Stock Analysis page.